HEMATOLOGY

Roswell Park Comprehensive Cancer Center has selected Jens Hillengass, MD, as its new Chief of Myeloma. Hillengass will continue his research on hematologic malignancies in his new position.

In a cohort of pediatric and young adult patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, adding nelarabine to escalating-dose methotrexate (C-MTX) induced a 4-year disease-free survival rate of 91%, according to findings released ahead of the 2018 ASCO Annual Meeting.

Daniel J. DeAngelo, MD, PhD, associate professor at the Harvard School of Medicine and a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, highlighted the 4 FDA approvals in the last year for the treatment of patients with acute myeloid leukemia.

Ivan Borrello, MD, recently shared the treatment considerations and decisions he makes when treating patients with multiple myeloma. Borrello, an associate professor of oncology, Johns Hopkins University School of Medicine, and director of cell therapy, Sydney Kimmel Comprehensive Cancer Center, in Baltimore, Maryland, explained his treatment decisions based on a case scenario during a <em>Targeted Oncology</em> live case-based peer perspective presentation.

In results published in April in the New England Journal of Medicine, corresponding author Peter J. M. Valk, PhD, of the Department of Hematology, Erasmus University Medical Center, and colleagues found that MRD positivity was associated with a higher rate of relapse and a lower rate of relapse-free survival and overall survival for patients with newly diagnosed AML.

Therapeutic Management of Immune Thrombocytopenia

Therapeutic Management of Immune Thrombocytopenia

Neil E. Kay, MD, professor of medicine at the Mayo Clinic, addresses the &ldquo;Big 4&rdquo; in salvage therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including a newer therapy coming down the pipeline now.

According to findings from the phase III QuANTUM-R study, overall survival was improved with quizartinib compared with chemotherapy in patients with&nbsp;<em>FLT3</em>-ITD&ndash;positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.<br /> &nbsp;

According to results from the MABLE trial, the combination of rituximab plus bendamustine demonstrated significant value as a frontline treatment option for fludarabine-ineligible patients with chronic lymphocytic leukemia.